Coronavirus

Pfizer says it identified antiviral compounds that have the potential to inhibit Coronavirus

cde.news desk 3 March 2020, 01:20 · 1 min read

epa08262121 An undated handout picture made available by the National Institutes of Health (NIH) shows a 3D print of a spike protein on the surface of SARS-CoV-2, also known as 2019-nCoV, the virus that causes Covid-19, in front of a 3D print of a SARS-CoV-2 virus particle (issued 01 March 2020). The spike protein (foreground) enables the virus to enter and infect human cells. On the virus model, the virus surface (blue) is covered with spike proteins (red) that enable the virus to enter and infect human cells. US health officials announced on 29 February 2020 the first confirmed death from the new coronavirus in the country in Washington State. The novel coronavirus is on the verge of spreading across the world as more Covid-19 cases are emerging outside China with outbreaks in South Korea, Italy and Iran. EPA-EFE/NATIONAL INSTITUTES OF HEALTH HANDOUT HANDOUT EDITORIAL USE ONLY/NO SALES

The pharmaceutical company Pfizer says it has identified certain antiviral compounds it had in development that have the potential to inhibit coronaviruses and is engaging with a third party to screen the compounds, Reuters reports.

The company said it hopes to have the results from that screening by the end of March and if any of the compounds are successful, it would hope start testing them by the end of the year.

Pfizer’ chief scientific officer, Mikael Dolsten, was one of a number of pharmaceutical executives who met with President Trump at the White House on Monday.

Via The Guardian

Filed under Coronavirus

Topics Coronavirus Healthcare Pfizer

Pfizer says it identified antiviral compounds that have the potential to inhibit Coronavirus

More from Coronavirus

Two million Britons suffer long COVID symptoms

CDC says JN.1 variant accounts for about 86% of COVID cases in US

WHO classifies JN.1 coronavirus strain as ‘variant of interest’